Cryoport (CYRX) Q2 Revenue Jumps 14%
Cryoport (NASDAQ:CYRX), a specialist in temperature-controlled supply chain solutions supporting cell and gene therapy and life sciences, reported its second quarter fiscal 2025 results on August 5, 2025. The most significant news was a double-digit revenue increase (GAAP, up 14% year-over-year) and greater-than-expected margin improvement (GAAP, gross margin from continuing operations increased to 47.0%), with total revenue (GAAP) at $45.5 million.—well ahead of consensus GAAP estimates of $41.7 million. Gross margin (GAAP) advanced to 47.0%, while the adjusted EBITDA loss improved to just $0.9 million. These results signal tangible progress on profitability, even though the company continues to report an adjusted EBITDA loss.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Cryoport is a global provider of solutions for the safe transport and storage of biological materials, with a strong presence in the fast-growing cell and gene therapy sector. The company offers Life Sciences Services such as logistics management, cryogenic storage, and biostorage services, as well as Life Sciences Products, including cryogenic freezers and monitoring equipment. Its services are designed to ensure the safe delivery and preservation of sensitive biological materials, which are critical for advanced therapies.
Source Fool.com
